Cabaletta Bio (CABA) is the lead sponsor of 5 active clinical trials listed on ClinicalTrials.gov[4], including 1 Phase 3[1], 5 Phase 2[2], 4 Phase 1[3].
Trial NCT06154252[5] evaluates CABA-201 following preconditioning with fludarabine and cyclophosphamide in Idiopathic Inflammatory Myopathy with a target enrollment of 74 participants.
No Form 4 insider filings for CABA were recorded at the SEC in the past 30 days[6].